Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional ...

The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...

Roivant Sciences (NASDAQ:ROIV) will release its quarterly earnings report on Thursday, 2025-05-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Roivant Sciences ...

Roivant and Priovant Therapeutics announced positive results from a phase 3 study of brepocitinib. The drug could have blockbuster potential in treating rare and orphan autoimmune diseases. Patients ...

The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. Roivant reported that its revenue for the period was slightly under $2.2 billion, ...

Ladies and gentlemen, thank you for standing by. Welcome to VALOR Phase III study results [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn ...

Spokespeople for Roivant and Vornado did not immediately respond to requests for comment. Ramaswamy founded Roivant in 2014 and transitioned out of his role as CEO in January 2021. He served as ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other best medical ...

Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...